Meet The NDAC, Minus One, As Conflict Of Interest Rules Come Into Play
This article was originally published in The Tan Sheet
Executive Summary
New Nonprescription Drugs Advisory Committee member James Kehrer's expertise on acetaminophen toxicity should make him a key figure at FDA's upcoming meeting on the drug, he says